Drug Profile
SR 271425
Alternative Names: BCN 326862; Cytolytic thioxanthone; SR271425; ThioxanthoneLatest Information Update: 17 Mar 2009
Price :
$50
*
At a glance
- Originator Sanofi-Synthelabo
- Developer sanofi-aventis; Sanofi-Synthelabo
- Class Antineoplastics
- Mechanism of Action Alkylating agents; DNA cross linking agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Leukaemia; Lymphoma; Solid tumours
Most Recent Events
- 27 Feb 2009 Discontinued - Phase-I for Solid tumours in Europe (IV-infusion)
- 26 Jul 2005 Data presented at the 41st Annual Meeting of the American Society of Clinical Oncology (ASCO-2005) have been added to the adverse events, pharmacokinetics and Cancer therapeutic trials sections ,,
- 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis